生成与异质性肿瘤微环境相关的胰腺癌类器官的方案。
Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment.
作者信息
Takeuchi Kenta, Tabe Shunsuke, Yamamoto Yuya, Takahashi Kenta, Matsuo Megumi, Ueno Yasuharu, Ohtsuka Masayuki, Morinaga Soichiro, Miyagi Yohei, Yamaguchi Tomoyuki, Tanimizu Naoki, Taniguchi Hideki
机构信息
Division of Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-0071, Japan.
Division of Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-0071, Japan; Department of General Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
出版信息
STAR Protoc. 2025 Mar 21;6(1):103539. doi: 10.1016/j.xpro.2024.103539. Epub 2025 Jan 7.
Pancreatic ductal adenocarcinoma (PDAC) organoids that simulate the tumor microenvironment (TME) are an effective tool to identify how TME affects PDAC malignancy. We present a protocol for generating a fused pancreatic cancer organoid (FPCO) that partly reproduces the TME, including heterogeneous cancer-associated fibroblasts (CAFs), using patient-derived PDAC cells and human-induced pluripotent cell-derived endothelial and mesenchymal cells. We also describe the procedure for analyzing FPCO characteristics. FPCO can provide a platform for establishing a reliable drug screening system. For complete details on the use and execution of this protocol, please refer to Takeuchi et al..
模拟肿瘤微环境（TME）的胰腺导管腺癌（PDAC）类器官是一种有效的工具，可用于确定TME如何影响PDAC的恶性程度。我们提出了一种生成融合胰腺癌类器官（FPCO）的方案，该方案使用患者来源的PDAC细胞以及人诱导多能细胞来源的内皮细胞和间充质细胞，部分重现了TME，包括异质性癌症相关成纤维细胞（CAF）。我们还描述了分析FPCO特征的程序。FPCO可为建立可靠的药物筛选系统提供一个平台。有关本方案使用和执行的完整详细信息，请参考Takeuchi等人的研究。
Zotero 插件